During the past decade, Spokane Eye Clinical Research conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 13 clinical trials were completed, i.e. on average, 43.3% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 11 clinical trials were completed. i.e. 73.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Spokane Eye Clinical Research" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Genentech, Inc." with 3 trials sponsored, "Allegro Ophthalmics, LLC" with 2 trials sponsored, "Allergan" with 2 trials sponsored and "Apellis Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Spokane Eye Clinical Research" #1 collaborator was "National Eye Institute (NEI)" with 3 trials as a collaborator, "Duke University" with 2 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 2 trials as a collaborator, "Trial Runners, LLC" with 2 trials as a collaborator and "Alder Hey Children's NHS Foundation Trust" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Spokane Eye Clinical Research" are "Geographic Atrophy" (7 trials), "Diabetic Macular Edema" (4 trials), "Neovascular Age-Related Macular Degeneration" (3 trials), "Age-Related Macular Degeneration" (2 trials) and "Amblyopia" (2 trials). Many other conditions were trialed in "Spokane Eye Clinical Research" in a lesser frequency.

Most popular intervention types in "Spokane Eye Clinical Research" are "Drug" (25 trials), "Other" (9 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (5 trials), "Faricimab" (4 trials), "Placebo" (3 trials), "Ranibizumab" (3 trials) and "Aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Spokane Eye Clinical Research" are 33 trials for "All" genders.

Currently, there are NaN active trials in "Spokane Eye Clinical Research". undefined are not yet recruiting, 6 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Spokane Eye Clinical Research, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Spokane Eye Clinical Research, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".